Literature DB >> 15549554

The role of neuroimaging in the diagnosis of headache in childhood and adolescence: a multicentre study.

G Mazzotta1, F Floridi, A Mattioni, R D'Angelo, B Gallai.   

Abstract

Following the diagnostic indications of the Guidelines for the diagnosis and therapy of juvenile headache, we present the results of a prospective, multicentre study of headache patients aimed at evaluating the utility of neuroradiologic testing in the diagnosis of headache. A total of 6535 subjects up to age 18 were studied, and 1485 underwent neuroimaging testing based on the indications of the diagnostic Flow-Chart. Abnormal results were observed in 273 (18.5%) subjects. Incidental findings were observed in 138 (9.3%) subjects, not correlated with the headache pathology, whereas alterations that led to the diagnosis of secondary headache were observed in 135 (9.1%) subjects. In conclusion, our data support a greater incidence of positive neuroimaging examinations among patients who underwent testing based on suspicion of a secondary headache pathology when compared with the low percentages observed in study populations.

Entities:  

Mesh:

Year:  2004        PMID: 15549554     DOI: 10.1007/s10072-004-0303-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  2 in total

Review 1.  Overview of diagnosis and management of paediatric headache. Part I: diagnosis.

Authors:  Aynur Ozge; Cristiano Termine; Fabio Antonaci; Sophia Natriashvili; Vincenzo Guidetti; Ciçek Wöber-Bingöl
Journal:  J Headache Pain       Date:  2011-02-27       Impact factor: 7.277

2.  Prevalence and Risk Factors Associated with Tumors and Other Structural Anomalies in Brain MRI Performed to Rule out Secondary Headache: A Multicenter Observational Study.

Authors:  José Pablo Martínez Barbero; Antonio Jesús Láinez Ramos-Bossini; Mario Rivera-Izquierdo; Francisco Sendra-Portero; José Manuel Benítez-Sánchez; Jorge A Cervilla
Journal:  Int J Environ Res Public Health       Date:  2022-03-16       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.